Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interaction between Herceptin and taxanes.

V Diéras1, P Beuzeboc, V Laurence

  • 1Department of Medical Oncology, Institut Curie, Service de Medecine Oncologique, Paris, France. veronique.dieras@curie.net

Oncology
|November 6, 2001
PubMed
Summary

Combining taxanes with Herceptin significantly improves treatment outcomes for metastatic breast cancer patients. This combination therapy enhances response rates and prolongs time to disease progression, showing effectiveness and good tolerability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.

Oncogene·2023
Same author

Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.

Oncogene·2023
Same author

Population pharmacokinetics and exposure-response relationship of trastuzumab and bevacizumab in early-stage breast cancer.

European journal of clinical pharmacology·2021
Same author

Corrigendum to "French ccAFU guidelines-update 2020-2022: Prostate cancer" [Prog. Urol 30 (12 S) (2020), pp S136-S251].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2021
Same author

[French ccAFU guidelines - update 2020-2022: prostate cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2020

Area of Science:

  • Oncology
  • Medical research
  • Pharmacology

Background:

  • Metastatic breast cancer treatment often involves taxanes and Herceptin.
  • Preclinical studies indicated additive and synergistic effects of taxane/Herceptin combinations.
  • HER2-positive breast cancer is a key target for targeted therapies like Herceptin.

Purpose of the Study:

  • To evaluate the clinical efficacy and safety of combining taxanes with Herceptin in metastatic breast cancer.
  • To compare combination therapy outcomes against taxane monotherapy.
  • To assess response rates in patients with varying HER2 tumor levels.

Main Methods:

  • Clinical trials involving paclitaxel or docetaxel in combination with Herceptin.
  • Evaluation of response rates, time to disease progression, and tolerability.

Related Experiment Videos

  • Studies included both 3-weekly and weekly taxane administration schedules.

    • Main Results:

    • Combination of paclitaxel (3-weekly) and Herceptin showed a higher response rate (41% vs. 17%) and improved time to disease progression (6.9 vs. 2.7 months) compared to paclitaxel alone.
    • Weekly paclitaxel plus Herceptin achieved a 60% response rate, with higher efficacy in HER2-overexpressing tumors (83%).
    • Preliminary data for Herceptin plus docetaxel (weekly or standard) also indicated significant activity, with response rates of 44% and 54%.

    Conclusions:

    • Regimens combining Herceptin with taxanes (both 3-weekly and weekly schedules) are effective and well-tolerated for metastatic breast cancer.
    • Combination therapy demonstrates superior outcomes compared to taxane monotherapy.
    • Ongoing trials are further investigating these combinations in various treatment settings.